The Scottish Medicines Consortium (SMC) has approved Ocrevus (ocrelizumab) as an NHS treatment for relapsing remitting multiple sclerosis in Scotland.
- Depression affected by lifestyle factors
- Gilenya approved for childhood MS
- Lemtrada warning issued
The European Commission has approved the extension of the licence for Gilenya (fingolimod) to include treatment of children and adolescents 10 years or older with relapsing remitting MS.
- Cognition affects ability to work
- Gender differences in diagnosis
- Rare Gilenya side effect warning
- Fampyra turned down in Scotland
- Heavy caseloads for MS specialist nurses
- Ocrevus slows progression in upper limbs
- Parenting with MS
- Trains and planes and disability
- Vitamin D recommendation
The MS Trust is delighted to announce that South Tees, NHS Lothian, Hull and North Lincs and Goole will be the next areas to benefit from our pioneering Specialist Nurse Programme.
The Scottish Medicines Consortium (SMC) has decided that fampridine (Fampyra) will not be made available on the NHS in Scotland for people with MS-related walking problems.
- The effect of pregnancy on MS
- Ocrevus for PPMS decision paused
- Coexisting conditions affect atrophy
- Medical cannabis rule change in Jersey
Radio 1 DJ Scott Mills, whose mum has MS, recently presented our BBC Lifeline Appeal. Here he tells us how his family have adapted to his mum’s MS diagnosis, the importance of speaking out about MS, and why his mum is his biggest inspiration.